Small molecule inhibitors of the HIV-1 virulence factor, Nef

Drug Discovery Today: Technologies

Volumn 10, Issue 4, 2013, Pages

  Smithgall, Thomas E ^a   Thomas, Gary ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS 1 VIRULENCE FACTOR NEF; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; NEF PROTEIN INHIBITOR; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COGNITIVE DEFECT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; PATHOGENESIS; QUALITY OF LIFE; VIRUS STRAIN;

ANIMALS; HIV INFECTIONS; HIV-1; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84886284138     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2013.07.002     Document Type: Review

References (43)

1. C. Aiken Nef induces CD4 endocytosis: requirement for a critical dileucine motif in the membrane-proximal CD4 cytoplasmic domain Cell 76 1994 853 864
2. A. Ali Synthesis and structure-activity relationship studies of HIV-1 virion infectivity factor (Vif) inhibitors that block viral replication ChemMedChem 7 2012 1217 1229
3. V.K. Arora Nef: agent of cell subversion Microbes Infect. 4 2002 189 199
4. K.M. Atkins HIV-1 Nef binds PACS-2 to assemble a multikinase cascade that triggers major histocompatibility complex class I (MHC-I) down-regulation: analysis using short interfering RNA and knock-out mice J. Biol. Chem. 283 2008 11772 11784
5. S. Betzi Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: application to the HIV-1 Nef protein Proc. Natl. Acad. Sci. U. S. A. 104 2007 19256 19261
6. A.D. Blagoveshchenskaya HIV-1 Nef downregulates MHC-I by a PACS-1- and PI3K-regulated ARF6 endocytic pathway Cell 111 2002 853 866
7. J. Bouchet Single-domain antibody-SH3 fusions for efficient neutralization of HIV-1 Nef functions J. Virol. 86 2012 4856 4867
8. S.D. Briggs SH3-mediated Hck tyrosine kinase activation and fibroblast transformation by the Nef protein of HIV-1 J. Biol. Chem. 272 1997 17899 17902
9. N. Chutiwitoonchai The identification of a small molecule compound that reduces HIV-1 Nef-mediated viral infectivity enhancement PLoS ONE 6 2011 e27696
10. N.J. Deacon Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients Science 270 1995 988 991
11. J.D. Dikeakos Small molecule inhibition of HIV-1-induced MHC-I down-regulation identifies a temporally regulated switch in Nef action Mol. Biol. Cell 21 2010 3279 3292
12. J.D. Dikeakos An interdomain binding site on HIV-1 Nef interacts with PACS-1 and PACS-2 on endosomes to down-regulate MHC-I Mol. Biol. Cell 23 2012 2184 2197
13. L. Emert-Sedlak Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds ACS Chem. Biol. 4 2009 939 947
14. L.A. Emert-Sedlak Effector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity Chem. Biol. 20 2013 82 91
15. J.R. Engen Structure and dynamic regulation of Src-family kinases Cell. Mol. Life Sci. 65 2008 3058 3073
16. J.L. Foster, and J.V. Garcia HIV-1 Nef: at the crossroads Retrovirology 5 2008 84
17. R. Guiet Hematopoietic cell kinase (Hck) isoforms and phagocyte duties - from signaling and actin reorganization to migration and phagocytosis Eur. J. Cell Biol. 87 2008 527 542
18. Z. Hanna Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice Cell 95 1998 163 175
19. Z. Hanna The pathogenicity of human immunodeficiency virus (HIV) type 1 Nef in CD4C/HIV transgenic mice is abolished by mutation of its SH3-binding domain, and disease development is delayed in the absence of Hck J. Virol. 75 2001 9378 9392
20. W. Huang Indolizine derivatives as HIV-1 VIF-ElonginC interaction inhibitors Chem. Biol. Drug Des. 81 2013 730 741
21. C.H. Hung HIV-1 Nef assembles a Src family kinase-ZAP-70/Syk-PI3K cascade to downregulate cell-surface MHC-I Cell Host Microbe 1 2007 121 133
22. X. Jia Structural basis of evasion of cellular adaptive immunity by HIV-1 Nef Nat. Struct. Mol. Biol. 19 2012 701 706
23. A.M. Joseph Nef: 'necessary and enforcing factor' in HIV infection Curr. HIV Res. 3 2005 87 94
24. H. Kestler Importance of the nef gene for maintenance of high viral loads and for development of AIDS Cell 65 1991 651 662
25. F. Kirchhoff Absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection N. Engl. J. Med. 332 1995 228 232
26. C-H. Lee Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain Cell 85 1996 931 942
27. L.X. Liu Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions J. Virol. 74 2000 5310 5319
28. A. Lugari A specific protein disorder catalyzer of HIV-1 Nef Bioorg. Med. Chem. 19 2011 7401 7406
29. M.H. Malim, and M. Emerman HIV-1 accessory proteins - ensuring viral survival in a hostile environment Cell Host Microbe 3 2008 388 398
30. I. Moarefi Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement Nature 385 1997 650 653
31. P.S. Narute, and T.E. Smithgall Nef alleles from all major HIV-1 clades activate Src-family kinases and enhance HIV-1 replication in an inhibitor-sensitive manner PLoS ONE 7 2012 e32561
32. E. O'Neill Dynamic evolution of the human immunodeficiency virus type 1 pathogenic factor, Nef J. Virol. 80 2006 1311 1320
33. C. Oneyama UCS15A, a novel small molecule, SH3 domain-mediated protein-protein interaction blocking drug Oncogene 21 2002 2037 2050
34. T. Pene-Dumitrescu HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck BMC Chem. Biol. 12 2012 1
35. J.A. Poe, and T.E. Smithgall HIV-1 Nef dimerization is required for Nef-mediated receptor downregulation and viral replication J. Mol. Biol. 394 2009 329 342
36. K. Saksela Interactions of the HIV/SIV pathogenicity factor Nef with SH3 domain-containing host cell proteins Curr. HIV Res. 9 2011 531 542
37. + viruses but not for down-regulation of CD4 EMBO J. 14 1995 484 491
38. Z. Temesgen Current status of antiretroviral therapy Expert Opin. Pharmacother. 7 2006 1541 1554
39. R.P. Trible HIV-1 Nef selectively activates SRC family kinases HCK, LYN and c-SRC through direct SH3 domain interaction J. Biol. Chem. 281 2006 27029 27038
40. O. Trott, and A.J. Olson AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading J. Comput. Chem. 31 2010 455 461
41. S.F. Walk Design and use of an inducibly activated human immunodeficiency virus type 1 Nef to study immune modulation J. Virol. 75 2001 834 843
42. H. Ye Oligomerization is required for HIV-1 Nef-induced activation of the Src family protein-tyrosine kinase, Hck Biochemistry 43 2004 15775 15784
43. W. Zou Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes Retrovirology 9 2012 44